Font Size:
 
 
 
Medical Professionals
 
 
Download Centre
 
 
Product Finder
 
 
Login
 
 
 
 
 
 
   
 
 
 
   
 
     
 
Overall Strategy

Augmentation of product portfolio: Our quest for new products and concepts never ends. We intend to further enhance our product portfolio across various therapy areas in the Acute and Chronic segments.

Acute portfolio and Chronic portfolio: We currently enjoy a dominant position in the Acute portfolio segment. Moving ahead in this segment, we plan to consolidate our Acute portfolio and further tighten our hold in the market. Simultaneously, we are concentrating our combined efforts to build our Chronic Portfolio. Overall, we intend to create a good balance of Acute and Chronic driven therapy areas.

Customer expansion/penetration: Customer expansion in terms of the target audience and Customer penetration in terms of the reach is an important strategic focus for us in the coming years in both domestic and International markets.

Continue focus on Brand Building: Brands are the strongest representator of our company and Brand building is a critical success factor in today’s competitive scenario. We at Alkem have always understood this crucial business need and have worked towards building the most envious brands in the Indian Pharmaceutical industry. Today Alkem has almost 11 brands in the list of top 300 best selling products of the industry. We also have over 28 brands worth more than $ 2 million in our product portfolio.

Build In-licensing and strategic alliances: We encourage marketing partnerships and product acquisition opportunities in all the markets where we operate. Alkem continues to explore market opportunities through Licensing and Alliances to draw maximum value from such arrangements. We continuously evaluate strategic opportunities to enhance our presence in various therapy areas.

For marketing alliances we work on non-infringement policies and completely respect intellectual property rights of our partners.

Some of the successful partnerships of Alkem include:
  Karo Bio - Sweden  
  Gnosis - Switzerland  
  Oculus - The Netherlands  
  Reyon - South Korea  
  Cargen - South Korea  
  Oculus Innovative Science - USA  
  Hor Phag - Switzerland  
 
     
 
   
     
 
  © Copyrights 2010 | Disclaimer